

Lionel Piroth

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9325501/publications.pdf>

Version: 2024-02-01

143
papers

5,099
citations

94433

37
h-index

98798

67
g-index

145
all docs

145
docs citations

145
times ranked

6073
citing authors

#	ARTICLE	IF	CITATIONS
1	A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial. <i>Lancet HIV</i> , 2022, 9, e79-e90.	4.7	18
2	Long-term Prognosis Following Vascular Graft Infection: A 10-Year Cohort Study. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac054.	0.9	9
3	A brain problem with <i>Listeria monocytogenes</i> . <i>Lancet Infectious Diseases</i> , 2022, 22, 296.	9.1	1
4	Incidence, associated factors, and effect on renal function of amoxicillin crystalluria in patients receiving high doses of intravenous amoxicillin (The CRISTAMOX Study): A cohort study. <i>EClinicalMedicine</i> , 2022, 45, 101340.	7.1	4
5	Tobacco use in people living with HIV: The need for complementary descriptive data to see beyond the smoke screen. <i>International Journal of Drug Policy</i> , 2022, 102, 103616.	3.3	1
6	Final results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19. <i>Lancet Infectious Diseases</i> , 2022, 22, 764-765.	9.1	8
7	Impact of Systematic Whole-body 18F-Fluorodeoxyglucose PET/CT on the Management of Patients Suspected of Infective Endocarditis: The Prospective Multicenter TEPvENDO Study. <i>Clinical Infectious Diseases</i> , 2021, 73, 393-403.	5.8	41
8	Atherosclerotic Cardiovascular Events in Patients Infected With Human Immunodeficiency Virus and Hepatitis C Virus. <i>Clinical Infectious Diseases</i> , 2021, 72, e215-e223.	5.8	6
9	Alveolar SARS-CoV-2 Viral Load Is Tightly Correlated With Severity in COVID-19 ARDS. <i>Clinical Infectious Diseases</i> , 2021, 72, e446-e447.	5.8	22
10	Impact on disease mortality of clinical, biological, and virological characteristics at hospital admission and overtime in COVID-19 patients. <i>Journal of Medical Virology</i> , 2021, 93, 2149-2159.	5.0	35
11	Corticosteroids in patients hospitalized for COVID-19 pneumonia who require oxygen: observational comparative study using routine care data. <i>Clinical Microbiology and Infection</i> , 2021, 27, 603-610.	6.0	12
12	Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study. <i>Lancet Respiratory Medicine</i> , 2021, 9, 251-259.	10.7	416
13	Is IL-6 the Right Target in COVID-19 Severe Pneumonia?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 139-140.	5.6	10
14	Cannabis use and reduced risk of elevated fatty liver index in HIV-HCV co-infected patients: a longitudinal analysis (ANRS CO13 HEPAVIH). <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 1147-1156.	4.4	6
15	Comparison of Cancer Patients to Non-Cancer Patients among COVID-19 Inpatients at a National Level. <i>Cancers</i> , 2021, 13, 1436.	3.7	31
16	Chronic use of renin-angiotensin-aldosterone system blockers and mortality in COVID-19: A multicenter prospective cohort and literature review. <i>Fundamental and Clinical Pharmacology</i> , 2021, 35, 1141-1158.	1.9	4
17	An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN- β -1a and hydroxychloroquine in hospitalized patients with COVID-19. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1826-1837.	6.0	77
18	Are adipokines the missing link between obesity, immune response, and outcomes in severe COVID-19?. <i>International Journal of Obesity</i> , 2021, 45, 2126-2131.	3.4	15

#	ARTICLE	IF	CITATIONS
19	Risk of severe clinical events after sustained virological response following direct-acting antiviral therapy in HIV and hepatitis C virus coinfecting participants. <i>HIV Medicine</i> , 2021, 22, 791-804.	2.2	1
20	Hydroxychloroquine in mild-to-moderate coronavirus disease 2019: a placebo-controlled double blind trial. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1124-1130.	6.0	34
21	Cancer and Infective Endocarditis: Characteristics and Prognostic Impact. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 766996.	2.4	9
22	Impact of the SARS-CoV-2 Epidemic on Lung Cancer Surgery in France: A Nationwide Study. <i>Cancers</i> , 2021, 13, 6277.	3.7	8
23	False-negative Results of Human Immunodeficiency Virus (HIV) Rapid Testing in HIV Controllers. <i>Clinical Infectious Diseases</i> , 2020, 70, 1754-1757.	5.8	1
24	Elevated Fatty Liver Index as a Risk Factor for All-Cause Mortality in Human Immunodeficiency Virus-Hepatitis C Virus-Coinfected Patients (ANRS CO13 HEPAVIH Cohort Study). <i>Hepatology</i> , 2020, 71, 1182-1197.	7.3	8
25	HCV-Related Mortality Among HIV/HCV Co-infected Patients: The Importance of Behaviors in the HCV Cure Era (ANRS CO13 HEPAVIH Cohort). <i>AIDS and Behavior</i> , 2020, 24, 1069-1084.	2.7	12
26	Procalcitonin to Distinguish Viral From Bacterial Origin of Pneumonia: No Premature Conclusion!. <i>Clinical Infectious Diseases</i> , 2020, 71, 246-247.	5.8	4
27	Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 628-639.	3.0	7
28	Isolated Anti-HBc: Significance and Management. <i>Journal of Clinical Medicine</i> , 2020, 9, 202.	2.4	22
29	Community-acquired bacterial meningitis in adults: in-hospital prognosis, long-term disability and determinants of outcome in a multicentre prospective cohort. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1192-1200.	6.0	35
30	Grazoprevir/elbasvir for the immediate treatment of recently acquired HCV genotype 1 or 4 infection in MSM. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1961-1968.	3.0	8
31	Elvitegravir-Cobicistat-Emtricitabine-Tenofovir Alafenamide Single-tablet Regimen for Human Immunodeficiency Virus Postexposure Prophylaxis. <i>Clinical Infectious Diseases</i> , 2019, 70, 943-946.	5.8	4
32	Increased liver stiffness is associated with mortality in HIV/HCV coinfecting subjects: The French nationwide ANRS CO13 HEPAVIH cohort study. <i>PLoS ONE</i> , 2019, 14, e0211286.	2.5	8
33	Outpatients With Acute Cough. <i>Chest</i> , 2019, 155, 1081-1082.	0.8	0
34	Prevalence and incidence of kidney diseases leading to hospital admission in people living with HIV in France: an observational nationwide study. <i>BMJ Open</i> , 2019, 9, e029211.	1.9	5
35	Real life-use of raltegravir during pregnancy in France: The Coferal-IMEA048 cohort study. <i>PLoS ONE</i> , 2019, 14, e0216010.	2.5	3
36	Staphylococcus aureus bloodstream infection in patients with prosthetic joint included in the prospective VIRSTA cohort study: frequency and time of occurrence of periprosthetic joint infection. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz515.	0.9	11

#	ARTICLE	IF	CITATIONS
37	Liver stiffness and fibrosis-4 alone better predict liver events compared with aspartate aminotransferase to platelet ratio index in a cohort of human immunodeficiency virus and hepatitis C virus co-infected patients from ANRS CO13 HEPAVIH cohort. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1387-1396.	1.6	4
38	Time to blood culture positivity: An independent predictor of infective endocarditis and mortality in patients with <i>Staphylococcus aureus</i> bacteraemia. <i>Clinical Microbiology and Infection</i> , 2019, 25, 481-488.	6.0	47
39	Dynamics in HIV DNA levels over time in HIV controllers. <i>Journal of the International AIDS Society</i> , 2019, 22, e25221.	3.0	21
40	Benefits and Limits of Antiretroviral Drug Monitoring in Routine Practice. <i>Current HIV Research</i> , 2019, 17, 190-197.	0.5	3
41	Comment on: Influence of empirical double-active combination antimicrobial therapy compared with active monotherapy on mortality in patients with septic shock: a propensity score-adjusted and matched analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1731-1735.	3.0	1
42	Four-days-a-week antiretroviral maintenance therapy in virologically controlled HIV-1-infected adults: the ANRS 162-4D trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 738-747.	3.0	20
43	Circulating cell-free DNA in patients with alveolar echinococcosis. <i>Molecular and Biochemical Parasitology</i> , 2018, 222, 14-20.	1.1	20
44	What do clinicians need to watch for with direct-acting antiviral therapy?. <i>Journal of the International AIDS Society</i> , 2018, 21, e25076.	3.0	10
45	No effect of vancomycin MIC ≤ 1.5 mg/L on treatment outcome in methicillin-susceptible <i>Staphylococcus aureus</i> bacteraemia. <i>International Journal of Antimicrobial Agents</i> , 2018, 51, 721-726.	2.5	8
46	Patients With Isolated Hepatitis B Core Antibody: Has the Time Come to Vaccinate?. <i>Clinical Infectious Diseases</i> , 2018, 66, 317-318.	5.8	4
47	First Case of Human Primary Vertebral Cystic Echinococcosis Due to <i>Echinococcus Ortleppi</i> . <i>Journal of Clinical Medicine</i> , 2018, 7, 443.	2.4	9
48	Determinants of high-grade anal intraepithelial lesions in HIV-positive men having sex with men. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2018, 5, S3.	4.5	0
49	Determinants of high-grade anal intraepithelial lesions in HIV-positive MSM. <i>Aids</i> , 2018, 32, 2363-2371.	2.2	23
50	Actinomycosis: An infrequent disease in renal transplant recipients?. <i>Transplant Infectious Disease</i> , 2018, 20, e12970.	1.7	7
51	Evolution of patients' socio-behavioral characteristics in the context of DAA: Results from the French ANRS CO13 HEPAVIH cohort of HIV-HCV co-infected patients. <i>PLoS ONE</i> , 2018, 13, e0199874.	2.5	3
52	Vertebral Hydatidosis. <i>New England Journal of Medicine</i> , 2018, 379, e5.	27.0	9
53	Factors associated with DAA virological treatment failure and resistance-associated substitutions description in HIV/HCV coinfecting patients. <i>World Journal of Hepatology</i> , 2018, 10, 856-866.	2.0	10
54	Hepatitis B virus vaccination in HIV-infected people: A review. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 1304-1313.	3.3	41

#	ARTICLE	IF	CITATIONS
55	Streptococcus pyogenes: an unusual cause of salpingitis. Case report and review of the literature. <i>Infection</i> , 2017, 45, 697-702.	4.7	3
56	Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients – French ANRS CO13 HEPAVIH cohort. <i>Journal of Hepatology</i> , 2017, 67, 23-31.	3.7	45
57	Significant reductions in alcohol use after hepatitis C treatment: results from the ANRS CO13-HEPAV IH cohort. <i>Addiction</i> , 2017, 112, 1669-1679.	3.3	10
58	Vaccine Education of Medical Students: A Nationwide Cross-sectional Survey. <i>American Journal of Preventive Medicine</i> , 2017, 53, e97-e104.	3.0	79
59	Effectiveness of and obstacles to antibiotic streamlining to amoxicillin monotherapy in bacteremic pneumococcal pneumonia. <i>International Journal of Antimicrobial Agents</i> , 2017, 50, 359-364.	2.5	2
60	Short article: Anger and quality of life in patients co-infected with HIV and hepatitis C virus: a cross-sectional study (ANRS CO13-HEPAV IH). <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 786-791.	1.6	4
61	Linezolid and atorvastatin impact on pneumonia caused by <i>Staphylococcus aureus</i> in rabbits with or without mechanical ventilation. <i>PLoS ONE</i> , 2017, 12, e0187187.	2.5	8
62	Duration of first-line antiretroviral therapy in HIV-infected treatment-naïve patients in routine practice. <i>Antiviral Therapy</i> , 2016, 21, 715-724.	1.0	0
63	Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study. <i>HIV Clinical Trials</i> , 2016, 17, 63-71.	2.0	4
64	Long-term Immune Response to Hepatitis B Virus Vaccination Regimens in Adults With Human Immunodeficiency Virus 1. <i>JAMA Internal Medicine</i> , 2016, 176, 603.	5.1	31
65	Hepatitis C: the path towards effective universal therapy. <i>Lancet</i> , The, 2016, 388, 1051-1052.	13.7	3
66	A New Prognosis Score to Predict Mortality After Acute Pneumonia in Very Elderly Patients. <i>Journal of the American Medical Directors Association</i> , 2016, 17, 1123-1128.	2.5	11
67	ITPA deficiency and ribavirin level are still predictive of anaemia in HCV – HIV-coinfected patients receiving ribavirin combined with a first-generation DAA (ANRS HC27 study). <i>Antiviral Therapy</i> , 2016, 22, 461-469.	1.0	0
68	All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus – coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13 – HEPAV IH Cohort. <i>Clinical Infectious Diseases</i> , 2016, 63, 763-770.	5.8	52
69	Vaccination Against Hepatitis B Virus (HBV) in HIV-1 – Infected Patients With Isolated Anti – HBV Core Antibody: The ANRS HB EP03 CISOVAC Prospective Study. <i>Journal of Infectious Diseases</i> , 2016, 213, 1735-1742.	4.0	27
70	Optimum combination therapy regimens for HIV/HCV infection. <i>Expert Review of Anti-Infective Therapy</i> , 2016, 14, 299-309.	4.4	2
71	The VIRSTA score, a prediction score to estimate risk of infective endocarditis and determine priority for echocardiography in patients with <i>Staphylococcus aureus</i> bacteremia. <i>Journal of Infection</i> , 2016, 72, 544-553.	3.3	82
72	Immunity, inflammation and reservoir in patients at an early stage of HIV infection on intermittent ART (ANRS 141 TIPI Trial). <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 490-496.	3.0	2

#	ARTICLE	IF	CITATIONS
73	Therapeutic management and evolution of chronic hepatitis B: does <scp>HIV</scp> still have an impact? The <scp>EPIB</scp> 2012 study. <i>Liver International</i> , 2015, 35, 1950-1958.	3.9	16
74	Direct-acting antiviral-based therapy for chronic hepatitis C virus in HIV-infected patients. <i>Current Opinion in HIV and AIDS</i> , 2015, 10, 337-347.	3.8	11
75	Raltegravir Pharmacokinetics in Patients on Asunaprevir-Daclatasvir. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 7903-7905.	3.2	2
76	Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a multicentre, open-label, randomised controlled trial. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 1283-1291.	9.1	45
77	High Cure Rate With 24 Weeks of Daclatasvir-Based Quadruple Therapy in Treatment-Experienced, Null-Responder Patients With HIV/Hepatitis C Virus Genotype 1/4 Coinfection: The ANRS HC30 QUADRIH Study. <i>Clinical Infectious Diseases</i> , 2015, 61, 817-825.	5.8	14
78	Influence of lifelong cumulative HIV viremia on long-term recovery of CD4+ cell count and CD4+/CD8+ ratio among patients on combination antiretroviral therapy. <i>Aids</i> , 2015, 29, 595-607.	2.2	19
79	Burden of <scp>HIV</scp> and hepatitis C co-infection: the changing epidemiology of hepatitis C in <scp>HIV</scp>-infected patients in France. <i>Liver International</i> , 2015, 35, 65-70.	3.9	26
80	Staphylococcus aureus infective endocarditis versus bacteremia strains: Subtle genetic differences at stake. <i>Infection, Genetics and Evolution</i> , 2015, 36, 524-530.	2.3	49
81	Staphylococcus aureus Bloodstream Infection and Endocarditis - A Prospective Cohort Study. <i>PLoS ONE</i> , 2015, 10, e0127385.	2.5	90
82	Use of first-generation <scp>HCV</scp> protease inhibitors in patients coinfecting by <scp>HIV</scp> and <scp>HCV</scp> genotype 1. <i>Liver International</i> , 2014, 34, 869-889.	3.9	4
83	Cohort Profile: French hospital database on HIV (FHDH-ANRS CO4). <i>International Journal of Epidemiology</i> , 2014, 43, 1425-1436.	1.9	70
84	In Vivo Efficacy of Ceftaroline Fosamil in a Methicillin-Resistant Panton-Valentine Leukocidin-Producing Staphylococcus aureus Rabbit Pneumonia Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1855-1861.	3.2	15
85	Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study. <i>Journal of Hepatology</i> , 2014, 61, 761-769.	3.7	14
86	Current management and recommendations on hepatitis B therapy in HIV-coinfected patients. <i>Hepatology International</i> , 2013, 7, 437-442.	4.2	3
87	The Respect of Recommendations Provided in an International Travelers' Medical Service: Far From the Cup to the Lips. <i>Journal of Travel Medicine</i> , 2013, 20, 78-82.	3.0	16
88	Short Communication: Paraoxonase 1 (PON1) in French HIV-Infected Patients Under Antiretroviral Therapy: Relationship with the Metabolic Syndrome and Inflammation. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 1571-1574.	1.1	4
89	Metabolic Syndrome in French HIV-Infected Patients: Prevalence and Predictive Factors After 3 Years of Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 1672-1678.	1.1	27
90	Ceftaroline versus Ceftriaxone in a Highly Penicillin-Resistant Pneumococcal Pneumonia Rabbit Model Using Simulated Human Dosing. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 3557-3563.	3.2	34

#	ARTICLE	IF	CITATIONS
91	Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis. <i>Journal of Hepatology</i> , 2011, 55, 756-761.	3.7	89
92	Relative impact of ribavirin monitoring and HIV coinfection on sustained virological response in patients with chronic hepatitis C. <i>Antiviral Therapy</i> , 2011, 16, 1317-1326.	1.0	6
93	Disseminated histoplasmosis with cutaneous lesions in an HIV patient. <i>European Journal of Dermatology</i> , 2011, 21, 128-129.	0.6	3
94	Safety and Immunogenicity of 4 Intramuscular Double Doses and 4 Intradermal Low Doses vs Standard Hepatitis B Vaccine Regimen in Adults With HIV-1. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 1432.	7.4	157
95	Gaining Greater Insight into HCV Emergence in HIV-Infected Men Who Have Sex with Men: The HEPAIG Study. <i>PLoS ONE</i> , 2011, 6, e29322.	2.5	45
96	Impact on Health-Related Quality of Life of a Switch From Enfuvirtide to Raltegravir Among Multidrug-Resistant HIV-1-Infected Patients: A Randomized Open-Label Trial (EASIER-ANRS 138). <i>HIV Clinical Trials</i> , 2010, 11, 283-293.	2.0	8
97	Ocular Syphilis and HIV Infection. <i>Sexually Transmitted Diseases</i> , 2010, 37, 41-43.	1.7	20
98	Treatment of acute hepatitis C in human immunodeficiency virus-infected patients: The HEPAIG study. <i>Hepatology</i> , 2010, 52, 1915-1921.	7.3	42
99	Response to anti-HCV therapy in HIV-HCV-coinfected patients: does the lipid profile really have an effect?. <i>Antiviral Therapy</i> , 2010, 15, 797-800.	1.0	3
100	Care of hepatitis C virus infection in human immunodeficiency virus-infected patients: Modifications in three consecutive large surveys between 2004 and 2009. <i>Journal of Hepatology</i> , 2010, 53, 230-237.	3.7	11
101	Management and treatment of chronic hepatitis B virus infection in HIV positive and negative patients: The EPIB 2008 study. <i>Journal of Hepatology</i> , 2010, 53, 1006-1012.	3.7	46
102	Coinfection with Hepatitis C Virus and HIV: More than Double Trouble. <i>Clinical Infectious Diseases</i> , 2009, 49, 623-625.	5.8	10
103	Bacterial epidemiology and antimicrobial resistance in ascitic fluid: A 2-year retrospective study. <i>Scandinavian Journal of Infectious Diseases</i> , 2009, 41, 847-851.	1.5	36
104	Contribution of (sub)domains of <i>Staphylococcus aureus</i> fibronectin-binding protein to the proinflammatory and procoagulant response of human vascular endothelial cells. <i>Thrombosis and Haemostasis</i> , 2009, 101, 495-504.	3.4	11
105	In vivo efficacy of humanised intermittent versus continuous ceftazidime in combination with tobramycin in an experimental model of pseudomonal pneumonia. <i>International Journal of Antimicrobial Agents</i> , 2008, 32, 494-498.	2.5	10
106	Prevalence and impact of GBV-C, SEN-V and HBV occult infections in HIV-HCV co-infected patients on HCV therapy. <i>Journal of Hepatology</i> , 2008, 49, 892-898.	3.7	13
107	The Fibrinogen- and Fibronectin-Binding Domains of <i>Staphylococcus aureus</i> Fibronectin-Binding Protein A Synergistically Promote Endothelial Invasion and Experimental Endocarditis. <i>Infection and Immunity</i> , 2008, 76, 3824-3831.	2.2	84
108	Occult hepatitis B in HIV-HCV coinfecting patients. <i>Scandinavian Journal of Infectious Diseases</i> , 2008, 40, 835-839.	1.5	21

#	ARTICLE	IF	CITATIONS
109	Treatment of chronic hepatitis C in HIV-infected patients: From clinical trials to field practice. <i>Scandinavian Journal of Infectious Diseases</i> , 2008, 40, 561-564.	1.5	6
110	Serum alpha-fetoprotein predicts virologic response to Hepatitis C treatment in HIV coinfecting patients. <i>Aids</i> , 2008, 22, 1513-1515.	2.2	3
111	Epidemiology, diagnosis and treatment of chronic hepatitis B in HIV-infected patients (EPIB 2005) <i>Tj ETQq1 1 0.784314 rgBT /Overloc</i>	2.2	53
112	Efficacy of humanlike Augmentin SR (2000/125 mg) twice daily treatment on <i>Haemophilus influenzae</i> experimental pneumonia in rabbits. <i>Scandinavian Journal of Infectious Diseases</i> , 2007, 39, 115-121.	1.5	1
113	Performance of a predictive rule to distinguish bacterial and viral meningitis. <i>Journal of Infection</i> , 2007, 54, 328-336.	3.3	57
114	Concentration of Circulating Oxidized LDL in HIV-Infected Patients Treated with Antiretroviral Agents: Relation to HIV-Related Lipodystrophy. <i>HIV Clinical Trials</i> , 2006, 7, 41-47.	2.0	38
115	Hepatic steatosis in HIV/HCV coinfecting patients: analysis of risk factors. <i>Aids</i> , 2006, 20, 525-531.	2.2	77
116	The impact of mechanical ventilation on the moxifloxacin treatment of experimental pneumonia caused by <i>Streptococcus pneumoniae</i> . <i>Critical Care Medicine</i> , 2005, 33, 1029-1035.	0.9	12
117	Fibrinogen and fibronectin binding cooperate for valve infection and invasion in <i>Staphylococcus aureus</i> experimental endocarditis. <i>Journal of Experimental Medicine</i> , 2005, 201, 1627-1635.	8.5	263
118	Spontaneous Hepatic Decompensation in Patients Coinfecting with HIV and Hepatitis C Virus during Interferon-Ribavirin Combination Treatment. <i>Clinical Infectious Diseases</i> , 2005, 41, 1806-1809.	5.8	41
119	Low Trough Plasma Concentrations of Nevirapine Associated with Virologic Rebounds in HIV-Infected Patients Who Switched from Protease Inhibitors. <i>Annals of Pharmacotherapy</i> , 2005, 39, 603-609.	1.9	38
120	Liver steatosis in HIV-infected patients. <i>AIDS Reviews</i> , 2005, 7, 197-209.	1.0	12
121	Pegylated Interferon Alfa-2b vs Standard Interferon Alfa-2b, Plus Ribavirin, for Chronic Hepatitis C in HIV-Infected Patients<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>; <i>JAMA - Journal of the American Medical Association</i> , 2004, 292, 2839.	7.4	742
122	In vivo pharmacodynamic efficacy of gatifloxacin against <i>Streptococcus pneumoniae</i> in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants. <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 54, 640-647.	3.0	48
123	Effect of Low-Level Resistance on Subsequent Enrichment of Fluoroquinolone-Resistant <i>Streptococcus pneumoniae</i> in Rabbits. <i>Journal of Infectious Diseases</i> , 2004, 190, 1472-1475.	4.0	38
124	Mutant Selection Window in Levofloxacin and Moxifloxacin Treatments of Experimental Pneumococcal Pneumonia in a Rabbit Model of Human Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 1699-1707.	3.2	72
125	Influence of positive end-expiratory pressure (PEEP) on histopathological and bacteriological aspects of pneumonia during low tidal volume mechanical ventilation. <i>Intensive Care Medicine</i> , 2004, 30, 2263-2270.	8.2	20
126	Usefulness of Therapeutic Drug Monitoring of Antiretrovirals in Routine Clinical Practice. <i>HIV Clinical Trials</i> , 2004, 5, 216-223.	2.0	17

#	ARTICLE	IF	CITATIONS
127	Clinical, Immunological and Virological Evolution in Patients with CD4 T-Cell Count above 500/mm ³ : Is there a Benefit to Treat with Highly Active Antiretroviral Therapy (HAART)? European Journal of Epidemiology, 2003, 19, 597-604.	5.7	5
128	Acute Liver Enzyme Elevations in HIV-1-Infected Patients. HIV Clinical Trials, 2003, 4, 400-410.	2.0	18
129	Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones. Journal of Antimicrobial Chemotherapy, 2002, 50, 349-360.	3.0	32
130	Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. Aids, 2002, 16, 21-29.	2.2	149
131	New model of ventilator-associated pneumonia in immunocompetent rabbits*. Critical Care Medicine, 2002, 30, 2278-2283.	0.9	26
132	The evolution of hepatitis B virus serological patterns and the clinical relevance of isolated antibodies to hepatitis B core antigen in HIV infected patients. Journal of Hepatology, 2002, 36, 681-686.	3.7	102
133	Evaluation of the Patient Medication Adherence Questionnaire As a Tool for Self-Reported Adherence Assessment in HIV-Infected Patients on Antiretroviral Regimens. HIV Clinical Trials, 2001, 2, 128-135.	2.0	86
134	Coronary heart disease associated with the use of human immunodeficiency virus (HIV) protease inhibitors: Report of four cases and review. Clinical Cardiology, 2001, 24, 690-694.	1.8	29
135	Fractional Maximal Effect Method for In Vitro Synergy between Amoxicillin and Ceftriaxone and between Vancomycin and Ceftriaxone against Enterococcus faecalis and Penicillin-Resistant Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy, 2001, 45, 3328-3333.	3.2	17
136	Rotavirus 2/6 Virus-Like Particles Administered Intranasally in Mice, with or without the Mucosal Adjuvants Cholera Toxin and Escherichia coli Heat-Labile Toxin, Induce a Th1/Th2-Like Immune Response. Journal of Virology, 2001, 75, 11010-11016.	3.4	61
137	Therapeutic Trials in HIV Infection: Which Benefits for Which Patients?. HIV Clinical Trials, 2001, 2, 22-30.	2.0	2
138	Value of Patient Self-Report and Plasma Human Immunodeficiency Virus Protease Inhibitor Level as Markers of Adherence to Antiretroviral Therapy: Relationship to Virologic Response. Clinical Infectious Diseases, 2001, 33, 386-392.	5.8	84
139	Recurrent NNRTI-Induced Hepatotoxicity in an HIV-HCV-Coinfected Patient. Annals of Pharmacotherapy, 2000, 34, 534-536.	1.9	8
140	Increased prevalence of subclinical hypothyroidism in HIV patients treated with highly active antiretroviral therapy. Aids, 2000, 14, 1070.	2.2	43
141	Development of a New Experimental Model of Penicillin-Resistant <i>Streptococcus pneumoniae</i> Pneumonia and Amoxicillin Treatment by Reproducing Human Pharmacokinetics. Antimicrobial Agents and Chemotherapy, 1999, 43, 2484-2492.	3.2	49
142	Spread of Extended-Spectrum β -Lactamase-Producing <i>Klebsiella pneumoniae</i> : Are β -Lactamase Inhibitors of Therapeutic Value?. Clinical Infectious Diseases, 1998, 27, 76-80.	5.8	95
143	Does hepatitis C virus co-infection accelerate clinical and immunological evolution of HIV-infected patients?. Aids, 1998, 12, 381-388.	2.2	178